Alzamend Neuro (NASDAQ:ALZN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Alzamend Neuro (NASDAQ:ALZN) from a sell rating to a hold rating in a report published on Saturday.

Separately, Ascendiant Capital Markets decreased their price objective on shares of Alzamend Neuro from $288.00 to $180.00 and set a “buy” rating for the company in a research report on Monday, March 17th.

Alzamend Neuro Trading Down 4.6%

Shares of NASDAQ ALZN opened at $3.09 on Friday. Alzamend Neuro has a 12-month low of $2.98 and a 12-month high of $135.54. The stock has a fifty day moving average price of $4.90 and a 200 day moving average price of $7.93.

Hedge Funds Weigh In On Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Geode Capital Management LLC acquired a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,540 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned about 0.62% of Alzamend Neuro at the end of the most recent reporting period. 49.61% of the stock is owned by hedge funds and other institutional investors.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.